2023 November China Export Data: E-Cigarettes to Russia

Industry Insight by Mincy
Dec.26.2023
2023 November China Export Data: E-Cigarettes to Russia
China's e-cigarette exports to Russia in November 2023 reached $69.24 million, with a MoM growth of 138.90% and YoY decline of 4.75%.

According to the updated trade data from the General Administration of Customs of the People's Republic of China, 2FIRSTS has compiled the e-cigarette export statistics to Russia in November 2023. The details are as follows:

2023 November China Export Data: E-Cigarettes to Russia
Image source: 2FIRSTS (Created by Mincy)

 

Exports reached approximately $69.24 million, marking a month-on-month increase of 138.90%, although a year-on-year decline of 4.75%.

2023 November China Export Data: E-Cigarettes to Russia
Image Source: 2FIRSTS (Graphics by Mincy)

 

The export volume reached approximately 1,561 tons, marking a 152.58% increase compared to the previous period and a 16.03% increase compared to the same period last year.

2023 November China Export Data: E-Cigarettes to Russia
Image source: 2FIRSTS (Mincy Design)

 

The export unit price dropped by 5.42% compared to the previous period and decreased by 17.91% compared to the same period last year, amounting to $44.36 per kilogram. The average price of "e-cigarettes and similar personal electronic vaporizers" was $8.10 per unit.

2023 November China Export Data: E-Cigarettes to Russia
Image source: 2FIRSTS (Mincy graphic)

 

Among them, "e-cigarettes and similar personal electronic vaporization devices" account for 18.69% of the export category, while "products that do not contain tobacco or reconstituted tobacco but contain nicotine and are non-combustible for inhalation" account for 81.31%.

2023 November China Export Data: E-Cigarettes to Russia
Source of the image: 2FIRSTS (Mincy graph)

 

We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn


Notice

1.  This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2.  The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3.  This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4.  Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

 

Copyright

 

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

 

AI Assistance Disclaimer

 

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

Qnovia’s Heat-Free Inhalable Nicotine Replacement Therapy Posts Positive First-in-Human Data, Advances FDA and MHRA Filings as Funding Expands
Qnovia’s Heat-Free Inhalable Nicotine Replacement Therapy Posts Positive First-in-Human Data, Advances FDA and MHRA Filings as Funding Expands
U.S.-based medical startup Qnovia Inc. reported positive results from its first-in-human clinical trial of RespiRx, an inhalable nicotine replacement therapy (NRT) device designed to support smoking cessation.
Innovation
Feb.24
Fiscal benefit, not health, strongest indicator for vape bans – Contributed by Samrat Chowdhery
Fiscal benefit, not health, strongest indicator for vape bans – Contributed by Samrat Chowdhery
Data shows 75% of nations with state stakes in tobacco trade ban modern substitutes compared to 10% in the free-market group. What is driving these divergent regulations?
Feb.04
Consultation opens for Tasmania’s Public Health Amendment Bill 2026
Consultation opens for Tasmania’s Public Health Amendment Bill 2026
Consultation opened on February 6, 2026 for the Public Health Amendment (Prohibited Tobacco and Other Products) Bill 2026. The Bill intends to address illicit trade in tobacco, nicotine pouches and e-cigarettes, which has increased significantly across Tasmania in recent years. It proposes changes to the Public Health Act 1997 to further protect the health of Tasmanians by reducing the sale and supply of illicit tobacco, vaping and other products, and to strengthen existing tobacco control laws.
Feb.06 by 2FIRSTS.ai
Azerbaijan parliament passes third-reading amendments introducing e-cigarette penalties, effective April 1, 2026
Azerbaijan parliament passes third-reading amendments introducing e-cigarette penalties, effective April 1, 2026
Azerbaijan’s Milli Majlis has adopted, in its third reading, amendments to the Code of Administrative Offences introducing fines and confiscation for the use of e-cigarettes and their components, as well as import, export, production, wholesale and retail sales, and storage for sale.
Mar.04 by 2FIRSTS.ai
France’s ANSES Report Reframes the Vape Debate: Harm Reduction Confirmed, Regulatory Barriers Rising
France’s ANSES Report Reframes the Vape Debate: Harm Reduction Confirmed, Regulatory Barriers Rising
France’s top health agency has confirmed that vaping is less harmful than smoking — but not risk-free — reshaping the country’s regulatory trajectory. As Paris withdraws a proposed vape tax and debates stricter ingredient, emissions and youth-protection rules, the ANSES report signals not prohibition, but tighter technical oversight. For manufacturers, retailers and EU policymakers, France may be previewing Europe’s next phase of nicotine governance.
Special Report
Feb.23
Philip Morris Japan adds “Electric Purple” to IQOS ILUMA i range, expands to convenience stores from Feb. 3
Philip Morris Japan adds “Electric Purple” to IQOS ILUMA i range, expands to convenience stores from Feb. 3
Philip Morris Japan (PMJ) said on Jan. 29 it has introduced “Electric Purple” as a new standard color option for its IQOS ILUMA i heated tobacco device lineup, covering three models with prices unchanged. The new color will be available from Jan. 29 via the company’s official online and store channels, with sales expanding to convenience stores and some tobacco retailers from Feb. 3.
Jan.29 by 2FIRSTS.ai